跳至主要内容
成分CosIng 更新 15 十月 2010

ARGININE HCL

L-Arginine hydrochloride

ARGININE HCL 列于欧盟 CosIng 清单,但本页尚未关联任何直接的附件记录。

一览

功能
Skin conditioning
CAS
1119-34-2
EC
214-275-1
欧盟附件
未列入未关联欧盟附件记录。这不是批准。

按市场划分的监管证据

此处跟踪的 13 个市场均未导入该成分的规则。

这描述的是本清单,而非法律。没有已导入的规则并不能证明某成分获准使用:规则可能以其他名称或标识符存在,或存在于尚未在此导入的数据集中。

ARGININE HCL 的清单详情

INCI 名称

ARGININE HCL

说明

L-Arginine hydrochloride

记录出处

清单参考
31985
已导入的身份
ARGININE HCL
来源更新
15/10/2010
欧盟委员会 CosIng 来源备注

关键数据

限制
—
功能

化学身份与性质

CAS 1119-34-2 的 PubChem 二维化学结构
CAS 1119-34-2PubChem CID 66250

L-Arginine, monohydrochloride

Arginine hydrochloride is a L-alpha-amino acid. — ChEBI

IUPAC 名称
(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;hydrochloride
分子式
C6H15ClN4O2
分子量
210.66 g/mol
精确质量
210.0883534 Da
拓扑极性表面积
128.0 Ų
氢键供体
5
氢键受体
4
共价单元
2
已定义的立体中心
1

又称

Arginine HydrochlorideL-ARGININE HCLR-GeneR-gene 10F7LTH1E20YNSC-203450NSC-7914Hydrochloride, arginine
另有 16 个已报告名称
NSC7914RefChem:5562214-275-1L-Arginine hydrochlorideL-Arginine monohydrochlorideH-Arg-OH.HClArginine HClArginine monohydrochlorideArgamineArgiveneDetoxarginL-(+)-Arginine monohydrochlorideLevarginL-Arginine, hydrochloride (1:1)Minophagen A(+)-L-Arginine hydrochloride
外部数据库标识符

来自其他科学数据库的证据

NIH PubChem PUG-View
标识符精确匹配66250

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism. 来源: Toxin and Toxin Target Database (T3DB)
  • Note: This chemical does not meet GHS hazard criteria for 67.8% (269 of 397) of all reports. 来源: European Chemicals Agency (ECHA)
  • Signal: Warning 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H315 (31.7%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (32.2%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 397 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 269 of 397 reports by companies.; There are 3 notifications provided by 128 of 397 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
  • Cosmetic Ingredient Review Finding(s): Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org 来源: Cosmetic Ingredient Review (CIR)
  • Toxicity Summary: Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues su 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

欧盟官方成分名称证据

该成分名称与 2025 年欧盟官方通用成分名称词汇表完全匹配。

配方功能重叠的成分

其他官方和科学来源

11 个可用于核查此身份的外部数据库

ARGININE HCL 在 CosIng 清单中的呈现方式

CosIng 清单将 ARGININE HCL 列为化妆品成分,本页将其关联到 0 条附件记录。清单条目记录名称和标识符,而附件记录显示该物质在欧盟化妆品法规中被禁用、限用或列入准用清单的情况。

在官方数据中,ARGININE HCL 还被标记了 1 项化妆品功能。功能标识描述预期用途,但不能取代在配方或标签工作之前对关联附件记录的监管审查。

常见问题

ARGININE HCL 列于欧盟 CosIng 成分清单,目前没有关联直接的附件限制记录。没有附件链接并不保证可无限制使用——配方前请务必对照现行官方 CosIng 数据库核实。

根据欧盟 CosIng 清单,ARGININE HCL 带有以下功能标识:

CAS 1119-34-2 可能出现在多条欧盟附件记录中。查看 CAS 查询页面可显示共用该标识符的所有附件 II–VI 条目,有助于识别同一化学物质在不同附件中的监管状态。

使用 INCI 检查器在选定市场中筛查完整成分表,或在所有受支持的市场数据集中对比该物质。

ARGININE HCL 的来源说明

本页转载欧盟委员会公开化妆品成分资料中 ARGININE HCL 的 CosIng 清单条目,即使目前没有附加直接的附件匹配,也会显示关联的标识符。

请使用本清单页面研究 ARGININE HCL 并对比关联记录,但在作出监管决定之前,请对照现行官方来源文本和法律核实限制和法律地位。

工具与后续步骤

检查您的配方

扫描完整的 INCI 成分表,检出 ARGININE HCL 及任何关联的欧盟附件限制或致敏原标记。

INCI 检查器

搜索相似成分

查找与 ARGININE HCL、其标识符或相近名称变体相关的其他清单成分和附件条目。

搜索